Solid had $213.7 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2022, compared to $207.8 million as of December 31, 2021. This financial position resulted from streamlined operating activities, the acquisition of AavantiBio, and a $75.0 million private placement. The Company expects that its cash, cash equivalents, and available-for-sale securities will enable it to fund key strategic priorities into 2025. "Following Solid Biosciences’ merger with AavantiBio and concurrent financing, Solid enters 2023 with an expanded pipeline encompassing both neuromuscular and cardiac indications, a proprietary capsid library and in-house manufacturing with a vector core, an experienced management team, and approximately $214 million of cash and investments. Our anticipated financial runway goes into 2025, and we are well-positioned to execute on our priorities and achieve key clinical milestones," said Bo Cumbo, President, and CEO of Solid Biosciences.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLDB:
- Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
- Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
- Solid Biosciences to Present at Barclays Global Healthcare Conference
- Solid Biosciences to Present at SVB Securities Global Biopharma Conference
- Pathway Development Consortium announces publication on DMD